To develop evidence-based clinical algorithms for community acquired-acute respiratory tract infections CA-ARTI and assess the diagnostic accuracy and the clinical utility of point-of-care tests (POCT) for specific groups of patients, clinical findings, and settings
To develop evidence-based URS’s to support future development and implementation of rapid diagnostics to reduce antimicrobial resistance (AMR) for CA-ARTI, and to refine the methods and processes to make them applicable to POC diagnostic developments for other infectious disease indications
To create a technical roadmap that incorporates recommendations for short- and long-term goals to help companies and research institutions prioritize investment decisions in the field of CA-ARTI diagnostics.
https://value-dx.eu/wp-content/uploads/2020/11/ispo.png7201280Tina Hoflandhttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngTina Hofland2020-11-17 14:29:442020-11-18 08:33:48VALUE-Dx at Virtual ISPOR Europe 2020
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2020-09-01 12:27:162020-11-18 08:34:25Webinar with the Expert Advisory Panel on September 30
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Tina Hoflandhttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngTina Hofland2020-06-26 11:31:312020-09-21 13:30:39Evaluating the clinical and cost-effectiveness of CA-ARTI diagnostics through PRUDENCE trial
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.